Trial Profile
The effect of Ezetimibe in hypercholesterolemic patients with Nonalcoholic fatty liver disease(NAFLD).
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Apr 2011
Price :
$35
*
At a glance
- Drugs Ezetimibe (Primary)
- Indications Hypercholesterolaemia
- Focus Biomarker; Pharmacodynamics
- 06 Oct 2009 New trial record